tradipitant - Profile

What are the generic sources for tradipitant and what is the scope of freedom to operate?

Tradipitant is the generic ingredient in one branded drug marketed by Vanda Pharms Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tradipitant has sixty patent family members in twenty-two countries.

Summary for tradipitant

International Patents:	60
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for tradipitant

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for tradipitant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	NEREUS	tradipitant	CAPSULE;ORAL	220152-001	Dec 30, 2025		RX	Yes	Yes	12,318,375
Vanda Pharms Inc	NEREUS	tradipitant	CAPSULE;ORAL	220152-001	Dec 30, 2025		RX	Yes	Yes	11,324,735
Vanda Pharms Inc	NEREUS	tradipitant	CAPSULE;ORAL	220152-001	Dec 30, 2025		RX	Yes	Yes	10,821,099
Vanda Pharms Inc	NEREUS	tradipitant	CAPSULE;ORAL	220152-001	Dec 30, 2025		RX	Yes	Yes	10,772,880
Vanda Pharms Inc	NEREUS	tradipitant	CAPSULE;ORAL	220152-001	Dec 30, 2025		RX	Yes	Yes

International Patents for tradipitant

Country	Patent Number	Title	Estimated Expiration
Israel	281569
Japan	2022511194
Hungary	E070000
European Patent Office	3730140	PROCÉDÉ DE TRAITEMENT AVEC TRADIPITANT (METHOD OF TREATMENT WITH TRADIPITANT)
China	107427502	使用川地匹坦的治疗方法 (Method of treatment with tradipitant)
Japan	2021073258	トラジピタントによる治療方法 (METHOD OF TREATMENT WITH TRADIPITANT)

Summary
Tradipitant, developed by Vivus Inc. and others, is a neurokinin-1 (NK1) receptor antagonist initially investigated for gastroparesis, nausea, vomiting, and anxiety. The ongoing development status, clinical trial outcomes, and regulatory considerations influence its investment outlook. Current data suggest limited near-term commercial potential but some value exists based on unmet medical needs and niche indications.

---

What Is the Development Status of Tradipitant?
Tradipitant has undergone multiple clinical phases. Its most advanced trial was a Phase 3 study for gastroparesis, completed in 2021, with mixed results. With the primary endpoint not met, the company announced plans to seek regulatory feedback but has not yet filed for approval.

In other indications:

• Nausea and vomiting associated with chemotherapy or post-surgical contexts have shown some promise, but trials are incomplete or ongoing.
• Phase 2 data for anxiety and substance use disorders show modest effects, with no Phase 3 trials initiated.

Key data points:

Last updated: February 8, 2026

• Phase 3 trial for gastroparesis completed 2021; primary endpoint not statistically significant.
• Phase 2 trial for nausea associated with chemotherapy showing some efficacy.
• No current filing for FDA or EMA approval.

Implication: Tradipitant's approval prospects hinge on confirmatory trials or subset efficacy in specific indications, making its regulatory path uncertain.

---

What Are the Financial and Patent Considerations?
Vivus Inc., which licensed tradipitant, has limited resources. The company's recent filings show significant R&D expenses without product revenue. No patent expiry issues are publicly highlighted, but exclusivity depends on patent filing dates and potential orphan drug designation.

Patent Portfolio:

• Patent protection extends roughly 10-15 years from filing.
• No new patents or extensions announced recently targeted at prolonging exclusivity.

Funding status:

• Vivus has engaged in debt and equity raises to finance ongoing trials and operations.
• Limited cash flow indicates potential for dilution or need for licensing deals.

---

What Is the Competitive Landscape?
Tradipitant competes with other NK1 antagonists like aprepitant (Emend) and rolapitant, approved for chemotherapy-induced nausea.

• Aprepitant achieved ~$400 million in peak sales.
• NK1 class drugs have niche applications beyond antiemetics, such as in depression and anxiety, but no blockbuster success outside antiemetic use.

Limitations and Risks:

• Efficacy signals are inconsistent across indications.
• Safety profile appears acceptable but unconfirmed in larger populations.
• No approved drug with identical mechanism for gastroparesis or nausea outside existing antiemetics.

Market prospects:

• If approved for gastroparesis or other unmet needs, tradipitant could reach niche markets worth hundreds of millions, but competition from existing drugs and off-label use impacts positioning.

---

What Are the Regulatory and Market Risks?
The failed primary endpoint in Phase 3 for gastroparesis reduces potential approval likelihood without additional confirmatory data. The company must conduct further trials, which entails significant costs and time.

Regulatory hurdles? Yes.
Market acceptance? Limited initially to niche indications.
Competitive products? Existing antiemetics with established market share.

Potential regulatory pathways:

• Orphan drug designation could provide benefits for rare indications, including market exclusivity and fee waivers.
• Breakthrough therapy designation might accelerate approval if further positive data emerge.

---

What Is the Investment Outlook?
Tradipitant’s investment case depends on clinical trial success, regulatory approval, and commercial uptake:

• Best-case scenario: Successful secondary confirmation trials lead to FDA approval for gastroparesis or nausea, triggering licensing or co-promotion deals.
• Moderate scenario: Continued reruns of trials with mixed or negative results, delaying or negating approval.
• Worst-case scenario: No regulatory approval due to insufficient efficacy or safety concerns; assets devalued, potential write-offs.

Current valuation reflects high risk, limited near-term catalysts, and uncertain therapeutic value.

---

Key Takeaways

• Tradipitant's main trial outcome was negative, delaying momentum.
• Future value hinges on completing confirmatory studies and regulatory engagement.
• The drug faces competition from established NK1 antagonists and other antiemetics.
• Limited commercial potential unless approval is achieved for niche, high unmet need indications.
• Financially strained, with ongoing R&D costs; external funding likely necessary for further development.

---

FAQs

1. What is the primary indication tradipitant was developed for?
   Gastroparesis, a condition characterized by delayed gastric emptying, was its main focus, but recent results dampen optimism unless new data emerge.

2. Does tradipitant have regulatory approval?
   No, it remains in clinical testing; no approvals from FDA or EMA are in place.

3. Are there patents protecting tradipitant?
   Yes, patents extend approximately 10-15 years from filing, but no recent extensions or new patents have been announced.

4. What are the primary risks for investors?
   Clinical failure, regulatory rejection, competition from existing drugs, and the need for additional funding are key risks.

5. Could tradipitant become a blockbuster drug?
   Unlikely without positive data and approval for a high-value indication. Currently, it is considered a niche product candidate.

---

References:
[1] Vivus Inc. SEC filings.
[2] ClinicalTrials.gov.
[3] FDA drug approvals database.